of apoptotic bodies was significantly decreased in the BRAF-mutant tumors. Mutation in the BRAF gene may contribute to colorectal carcinogenesis by up-regulating the anti-apoptotic role of the RAS/RAF/MEK/ERK pathway.
INTRODUCTION
The development of colorectal cancer is a multi-step process characterized by the accumulation of genetic alterations. 1 The RAS proto-oncogene is mutated to an oncogenic form in about 30% of human cancers, and frequent K-ras mutations have been reported in pancreatic, colorectal, and lung cancers. [1] [2] [3] [4] Especially, alterations in K-ras at codons 12, 13, and 61 lead to increased unregulated cellular proliferation and malignant transformation. 5 In human colorectal cancers, K-ras mutation has been considered an early event in the development of adenomas. This genetic event is more common in large adenomas than small ones, suggesting that it may be required for the activation of adenoma progression in the RAS/RAF/MEK/ERK pathway. 1, 6 Therefore, up-regulation of RAS-regulated intracellular signaling is necessary for colorectal tumorigenesis.
Genes of the RAF family encode RAS-regulated kinases and mediate cellular responses to growth signals. 7 Recently, the activation of BRAF, one of the three RAF members, has been reported to occur by somatic mutation in many human cancers, particularly in human malignant melanoma (over 60%), 8, 9 human colorectal cancers (5-15%), 8, 10, 11 and a small fraction of other cancers. 8 Frequent mutations in the BRAF gene have been detected in the two regions of the BRAF kinase domain: the G-loop in exon 11 and the activation segment in exon 15. 8 The majority of the BRAF mutations each represent a single nucleotide change of T-A at nucleotide 1796, resulting in the change of valine to glutamic acid at codon 599 within the activation segment of BRAF. 8 Moreover, a previous report showed that overexpression of BRAF could act as a potent inhibitor of apoptosis by activating the BRAF/MEK/ERK pathway, which interferes with apoptosis at the level of cytosolic caspase activation and consequently inhibits the release of cytochrome c from mitochondria. 12 Although BRAF mutations were found in about 5-15% of colorectal carcinomas, colorectal carcinomas with BRAF mutations tended to be in lower clinical tumor stages. 11 However, it has been suggested that alteration in the BRAF gene may cause the activation of the RAS/RAF/MEK/ERK pathway, consequently increasing cell proliferation but suppressing the inhibition of apoptosis.
Furthermore, although the acquisition of a BRAF mutation have been associated with the progression of hyperplastic polyp to serrated adenoma, 13 further investigations are needed to clarify the role of mutant BRAF in human colorectal tumorigenesis.
To elucidate the roles of K-ras and BRAF oncogenic mutations in colorectal tumorigenesis, we analyzed the effects of an RAS inhibitory agent, FTI-277, on colon cancer cell lines. We investigated BRAF mutations in human colorectal tumors and correlation relationships among clinicopathologic parameters. An immunohistochemical study was also performed to evaluate the correlation with the Ki-67 labeling index and the number of apoptotic bodies in this series of colorectal tumors. 
MATERIALS AND METHODS

Cell lines and tissue samples
Apoptotic bodies and DNA fragmentation
After treatment with FTI-277, apoptotic (sub-G1 phase) LoVo and WiDr cells were counted after staining with propidium iodide (Molecular Probes, Eugene, OR).
The number of apoptotic bodies was determined by counting the apoptotic cells (%) in a total of more than 300 cells. To detect apoptotic DNA fragmentation, genomic DNA was extracted from members of both cell lines as described elsewhere. 17 Cells treated with FTI-277 and GW5074 were lysed in a buffer containing 50 mM Tris-HCl (pH 7.8),
10 mM EDTA, and 0.5% sodium N-lauroylsarcosinate. Next, the lysates were incubated with 1 µg RNase A and then 1 µg of proteinase K at 50 °C for 30 minutes each, and were then electrophoresed in 1% agarose gels.
PCR-SSCP and direct sequencing analyses
Mutations in exons 11 and 15 of the BRAF gene and exon 2 of the K-ras gene were examined by PCR-SSCP analysis using the following primer sets: BRAF-exon 11, and an automated ABI PRISM 310 DNA sequencer (Applied Biosystems).
Immunohistochemistry
Immunohistochemistry was investigated to study the proliferative activity and induction of apoptosis in colorectal neoplastic tissues. A mouse monoclonal antibody against Ki-67 (Immunotech, Marseille, France) and a rabbit polyclonal antibody to single-stranded DNA (ssDNA; DAKO, Glostrup, Denmark) were used as primary antibodies. A modified version of the immunoglobulin enzyme bridge technique was used as described elsewhere. 18 Briefly, deparaffinized tissue sections were immersed in 10 mM sodium citrate buffer, and pretreatment autoclaving was performed to retrieve antigenicity, except for ssDNA sections. Endogenous peroxidase activity and 
Statistical analysis
The efficacies of FTI-277 in the growth and induction of apoptosis in human colon cancer cell lines, as well as the relationships among clinicopathological parameters, were determined using the χ 2 test, one-factor ANOVA and Fisher's PLSD test. A level of P < 0.05 was taken to be statistically significant.
RESULTS
The growth-inhibitory and apoptosis-inducing effects of FTI-277 in colon cancer cell lines
To investigate the roles of K-ras and BRAF in human colon cancer cell lines, we first examined mutations of the BRAF and K-ras genes in 7 human colon cancer cell lines. Of these, 2 cell lines contained alterations in the BRAF gene (WiDr and TCO, 28%), while 4 cell lines (LoVo, DLD-1, SW480, and HCT-15, 57%) contained alterations in the K-ras gene (Fig. 1) . Missense mutations at codon 599 (V599E) were detected in both the WiDr and TCO BRAF-mutant cell lines, and missense mutations at codon 12 (G12V) or codon 13 (G13D) were detected in the K-ras-mutant cell lines, LoVo, DLD-1, SW480, and HCT-15. None of the cell lines showed neither BRAF mutation nor K-ras mutation (Table II) .
Next, the growth-inhibitory effects of FTI-277 in these BRAF-mutant and K-ras-mutant cell lines were analyzed to investigate the role of the RAS/RAF/MEK/ERK pathway in these cells. As shown in Fig. 2A , when the LoVo cells were treated with 10 µM or 20 µM FTI-277 after serum starvation for 24 hours, cell proliferation decreased significantly, to 33% or 19%, respectively, in a concentration-dependent manner. In contrast, FTI-277 did not affect cell growth in treatment with FTI-277 did not interfere with the levels of phosphorylated MEK and ERK expression (Fig. 2B) . Moreover, we counted the apoptotic bodies in the current series of human colon cancer cell lines to show the relationship between FTI-277 and the induction of apoptosis. Although FTI-277 did not affect the induction of apoptosis in WiDr cells (< 2%), the number of apoptotic bodies increased significantly (P = 0.002)
in LoVo cells (8-12%) in a concentration-dependent manner (Fig. 2C) . We confirmed the induction of apoptosis in LoVo cells by detecting an apoptotic DNA ladder (Fig.   2D ).
Mutation analyses of BRAF and K-ras genes in human colorectal cancers and relationship with clinicopathological parameters
To detect mutations in BRAF and K-ras genes, we performed PCR-SSCP analysis and direct sequencing in the same of 116 colorectal tumors samples. BRAF mutations were found in 1 (3.0%) of 33 colorectal adenomas and 6 (7.2%) of 83 colorectal adenocarcinomas (Table III) . Interestingly, the adenoma with the BRAF mutation showed a serrated glandular structure (serrated adenoma), but no BRAF alteration was found in the tubular adenomas. Most of the tumors demonstrated missense mutations at codon 599 (V599E), and a mutation at codon 468 (G468V) was detected in one adenocarcinoma (Fig. 3) . Overall, mutations in the K-ras gene were detected in 2 (6.0%) of 33 colorectal adenomas and 22 (26.5%) of 83 colorectal adenocarcinomas. We found that none of the tumors contained mutations in both the BRAF and K-ras genes.
Next, we analyzed the relationship among clinicopathologic findings in this series of colorectal tumors. Of the 6 colorectal cancers with BRAF mutations, 2 (33.3%)
were early colorectal cancers and 4 (66.7%) were advanced. Colorectal tumors with K-ras and BRAF mutations were larger than wild-type colorectal tumors (p = 0.0042).
Moreover, the incidence of lymph node metastasis was more frequent in K-ras and BRAF-mutant colorectal cancers (p = 0.0459), and colorectal cancers with K-ras or BRAF mutations tended to be in more advanced clinical stages (p = 0.0076) than colorectal tumors with wild-type K-ras and BRAF (Table IV) . To clarify the differences in proliferation and apoptosis in colorectal neoplasms with alterations in the BRAF or K-ras genes, we investigated Ki-67 labeling index and the numbers of apoptotic bodies in tumor cells (Fig. 4A) . Interestingly, although the proliferative activity was not statistically significant between BRAF and K-ras mutations (Fig. 4B) , the number of apoptotic bodies was significantly suppressed in colorectal neoplasms with BRAF mutations (p = 0.0285) ( Figure 4C ). Furthermore, the index values of apoptotic bodies by the TUNEL method was significantly reduced in colorectal tumors with BRAF mutations as well as by using a polyclonal antibody specific to ss-DNA (data not shown).
DISCUSSION
The RAS/RAF/MEK/ERK pathway is at the heart of signaling networks that govern proliferation, differentiation, and cell survival. 19 In the development of human colorectal carcinomas, alterations in K-ras gene are frequently the cause of dysfunction in this intracellular signaling. In this study, we detected genetic changes in the BRAF gene in 7.2% of colorectal cancers, a rate nearly congruent with that in a previous report. 11 In addition, most BRAF mutations in colorectal tumors were detected at a mutation hot spot, codon 599 (V599E). 9,10,11 V599E mutations have been reported to show greatly increased activity in the BRAF/MEK/ERK pathway, both in vitro and in vivo, 8 and mutation at codon 599 was shown to activate NFκB-dependent signaling. 20 Moreover, suppression of BRAF V599E expression by RNA interference in cultured human melanoma inhibited the mitogen-activated protein kinase cascade, consequently arresting growth and the promoting apoptosis. 21 Interestingly, we found a novel mutation at codon 468 (G468V), located in the glycine residues of the GXGXXG motif within the glycine-rich loop of the kinase domain. A previous report showed that mutation of the glycine residues in the GXGXXG motif of the ATP-binding domain could activate kinases. 8 To our knowledge, this is the first report of a BRAF mutation with a single nucleotide change of G-T at nucleotide 1403 in human malignancies.
RAS has been shown to regulate several pathways that contribute to cellular transformation, such as the Rac, Rho, and RAS/RAF/MEK/ERK pathways. 22 Since a single-point mutation of the RAS gene can lead to its constitutive activation of RAS protein, knocking out the activated K-ras gene in the human colon cancer cell lines DLD-1 and HCT-116 resulted in cell lines incapable of clone formation on soft agar and lacking tumorigenicity in nude mice. 23 Mutations of the RAS gene in colon and pancreatic cancers were found only in K-ras, especially in the early stage of carcinogenesis. In this study, we detected genetic changes in the K-ras gene in 6.0% and 26.5% of colorectal adenomas and cancers, which is in conflict with previous reports.
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Moreover, we found that none of the tumors contained mutations in both the BRAF and K-ras genes, indicating that the coincidence of BRAF and K-ras mutations in the same colorectal sample would be a rare event. 11 Our data suggest that an alteration in the BRAF gene may contribute to activation of the RAS/RAF/MEK/ERK pathway signaling in human colorectal tumorigenesis, independent of K-ras mutation.
As described above, clinicopathological similarities in colorectal tumors with K-ras or BRAF mutations may reflect a role for the RAS/RAF/MEK/ERK pathway in colorectal tumorigenesis. In our analysis, colorectal cancers with altered BRAF or K-ras genes showed frequent lymph node metastasis with advanced clinical stages. However, our results were in disagreement with a previous report, which exhibited that colorectal carcinomas with BRAF mutations tend to be at a lower clinical stage. 11 Our observations suggested that colorectal neoplasms with BRAF or K-ras mutations may have almost the same clinicopathological features, whereas BRAF gene alterations of colorectal tissues were associated with significant decreases in rates of cell apoptosis in tumor cells. In contrast, colorectal tumors of BRAF or K-ras mutations were not associated with a significant increase in the rates of cell proliferative activities. These findings suggest that the development and progression of BRAF-mutant colorectal neoplasms may be closely associated with the dysregulation of apoptosis induction.
Chan et al. 13 found that the high frequencies of BRAF mutations in hyperplastic polyp (30%) and serrated adenoma (100%) contrasted sharply with the low incidence observed in classical adenomas. In our samples, BRAF mutations were found in 50% of serrated adenomas. Furthermore, we analyzed alterations in the BRAF and K-ras genes in flat-typed colorectal cancer 24, 25 without an adenomatous component, and found alterations in BRAF and K-ras genes were in 15% and 0% of the tumors, respectively (data not shown). These data may suggest that alteration in the BRAF gene is, like that in the K-ras gene, an early event in the adenoma-carcinoma sequence of the colorectum, and that alteration in the BRAF gene may be related to the progression/development of colorectal cancer arising de novo. Further investigation will be needed to clarify the roles of BRAF in the multistep carcinogenesis of the colorectum. human melanoma cells cause growth arrest and promote apoptosis, and these consequences prevent colony formation in suspension. 21 Our in vitro studies using G35A  G12D  F  D  22  2  mod  T2  I   G35A  G12D  M  D  40  2  por  T3  III   G35A  G12D  F  P  80  2  mod  T3  III   G35A  G12D  M  D  38  2  wel  T3  II   G35A  G12D  M  D  50  2  wel  T3  III   G35A  G12D  M  P  50  0-Isp  wel  Tis  0   G35A  G12D  M  D  12  0-Isp  wel  Tis  0   G35A  G12D  M  P  30  0-Isp  wel  T1  I   G35A  G12D  F  P  45  0-IIa  wel  Tis  0   G38A  G13D  M  P  80  2  wel  T3  II   G38A  G13D  F  P  35  2  mod  T3  III   G38A  G13D  F  D  60  2  mod  T3  III   G38A  G13D  F  D  45  2  mod  T3  III   G38A  G13D  M  D  8  0-Isp  wel  Tis  0   G38A  G13D  F  D  32  0-IIa  wel  Tis  0   G38A  G13D  M  P  34  0-IIa  wel  Tis  0   G34T  G12C  M  D  30  2  wel  T3  II   G34T  G12C  F  D  50  2  mod  T3  IV   G34A  G12S  F  D  45  2  mod  T3  IV   G34A  G12S  M  P  26  0-IIa  wel  T1  I   G37T  G13C  F  D  25  IIa  TA   c   --G34C  G12R  M  D  11  Ip  TVA   d -- 
